Skinvisible Stock Price, News & Analysis

Skinvisible, Inc. (OTCQB: SKVI) is a pharmaceutical research and development company focused on topical and transdermal drug delivery. Through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., the company specializes in developing and licensing proprietary formulations that use its patented polymer skin delivery system known as Invisicare®.

Skinvisible operates in the pharmaceutical preparation manufacturing industry, with an emphasis on dermatology-related conditions and systemic therapies delivered through the skin. According to company disclosures, Invisicare is formulated as a lotion or cream that adheres active ingredients to the skin and facilitates controlled release of those actives to and/or through the skin and into the bloodstream over time.

Business model and Invisicare technology

Skinvisible describes itself as a research and development company that focuses on licensing proprietary topical and transdermal formulations built on Invisicare. Rather than marketing finished products itself, the company licenses its technology and formulations to pharmaceutical and biotech partners, who are then responsible for conducting clinical development, obtaining regulatory approvals and commercializing products in various markets.

The Invisicare platform is presented as a polymer-based skin delivery system that can be incorporated into lotions or creams. The company states that this system is designed to:

• Bind active ingredients to the skin surface
• Enable controlled and sustained release of drugs over time
• Deliver actives either topically (to the skin) or transdermally (through the skin and into the bloodstream)

Skinvisible indicates that Invisicare can be used for life-cycle management of existing drugs and for creating distinctive enhancements in topical and transdermal delivery products, by modifying how and how long active ingredients are presented to the skin.

Focus areas: rare skin diseases and obesity-related formulations

Based on company communications, Skinvisible has developed formulations for the potential treatment of over forty dermatology-related conditions, including rare skin disorders. One key area of activity is its collaboration with Quoin Pharmaceuticals, Inc. (NASDAQ: QNRX) around the product candidate QRX003 for Netherton Syndrome, a hereditary disorder affecting the skin, hair and immune system that currently lacks an approved treatment or cure.

Skinvisible granted Quoin an exclusive, royalty-bearing license to use Invisicare technology and a proprietary formula for Netherton Syndrome and select rare skin diseases. Quoin is responsible for obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals in the United States and other countries. Skinvisible reports that, upon successful completion of FDA or European Union approval milestones, it is entitled to a milestone payment and ongoing royalties from sales.

In addition to rare dermatological conditions, Skinvisible has disclosed an active focus on transdermal obesity and glucose-controlling formulations. The company has filed provisional patent applications covering formulations that use Invisicare for the transdermal administration of:

• GLP-1 receptor agonists
• CB-1 receptor antagonists
• Other glucose-controlling agents, including SGLT-2 inhibitors as described in a later patent application

These formulations are described as topical creams or lotions that can deliver active ingredients through the skin without the need for patches or needles, with the goal of achieving sustained systemic delivery while avoiding first-pass metabolism through the gastrointestinal tract and liver.

Preclinical and formulation data disclosed

Skinvisible has reported results from Franz cell diffusion studies evaluating Invisicare-based obesity and glucose-controlling formulations. According to the company, these studies demonstrated:

• Transdermal penetration over a six-hour period for a GLP-1 drug formulated with Invisicare
• Transdermal penetration over a six-hour period for CB-1 antagonists formulated with Invisicare
• Sustained drug delivery over time, with data indicating ongoing release rather than an initial spike

The company has also highlighted data indicating significant transdermal delivery of a GLP-1 active and notable penetration for CB-1 antagonists in laboratory diffusion models. These results are presented as support for the potential of Invisicare to deliver obesity-targeting and glucose-controlling agents transdermally.

Regulatory milestones via licensees

Skinvisible’s Invisicare technology has reached key regulatory milestones through its licensees. The company reports that the QRX003 formulation for Netherton Syndrome, which uses Invisicare, has received U.S. FDA acceptance of an Investigational New Drug (IND) application. Clinical studies sponsored by Quoin have generated:

• Positive initial data with a reported clean safety profile
• Protocol amendments and optimization plans, including increased trial size and adjusted dosing frequency
• Clinical observations in Netherton Syndrome subjects, including improvements in disease classification in some cases over defined dosing periods

Skinvisible characterizes the IND acceptance and ongoing clinical progress for QRX003 as important validation of its strategy to develop topical therapeutics using Invisicare for rare skin diseases.

Therapeutic scope and research pipeline

According to company descriptions, Skinvisible’s research pipeline spans:

• Rare dermatology indications, such as Netherton Syndrome and other rare skin disorders licensed to Quoin
• Obesity and metabolic conditions, through transdermal formulations of GLP-1 agonists, CB-1 antagonists and other glucose-controlling agents
• Additional dermatology-related conditions, with the company stating it has developed formulations for more than forty skin-related indications

Skinvisible continues to develop new formulations incorporating obesity and glucose-targeting active ingredients that it has identified for their transdermal penetration and stability when combined with Invisicare. The company’s communications emphasize that Invisicare-based creams and lotions are intended to provide a needle-free alternative to injections and an option that bypasses the digestive system.

Partnership and licensing strategy

Across its public statements, Skinvisible highlights an ongoing effort to seek strategic partnerships with pharmaceutical and biotech companies. The company’s model centers on:

• Developing Invisicare-based topical and transdermal formulations
• Licensing these formulations and underlying technology to partners
• Relying on partners to conduct clinical development and secure regulatory approvals
• Receiving milestone payments and royalties tied to regulatory success and product sales

This approach aligns with Skinvisible’s positioning as a specialized R&D and licensing company within the pharmaceutical preparation manufacturing sector, rather than as a fully integrated commercial drug manufacturer.

Industry classification and trading venue

Skinvisible, Inc. is classified in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. The company’s shares trade on the OTCQB market under the ticker symbol SKVI. Its activities are centered on the development and licensing of proprietary topical and transdermal drug delivery formulations based on its patented Invisicare polymer skin delivery system.

FAQs about Skinvisible, Inc. (SKVI)

• What does Skinvisible, Inc. do?
  Skinvisible, Inc., through Skinvisible Pharmaceuticals, Inc., focuses on researching, developing and licensing topical and transdermal pharmaceutical formulations built on its patented Invisicare polymer skin delivery system.
• What is Invisicare technology?
  Invisicare is Skinvisible’s patented polymer skin delivery system that can be formulated as a lotion or cream. It is designed to adhere active ingredients to the skin and provide controlled release to and/or through the skin and into the bloodstream over time.
• How does Skinvisible generate revenue from its technology?
  According to company disclosures, Skinvisible licenses its Invisicare-based formulations and technology to pharmaceutical and biotech partners. These agreements can include milestone payments tied to regulatory approvals and ongoing royalties from product sales.
• What therapeutic areas does Skinvisible target?
  Skinvisible reports that it has developed formulations for the potential treatment of obesity and for more than forty dermatology-related conditions, including rare skin disorders. Its work includes rare diseases such as Netherton Syndrome and obesity-related and glucose-controlling indications.
• What is QRX003 and how is Skinvisible involved?
  QRX003 is a topical lotion developed by Quoin Pharmaceuticals that uses Skinvisible’s Invisicare delivery technology and contains a broad-spectrum serine protease inhibitor. It is being investigated for Netherton Syndrome under an FDA-accepted IND, and Skinvisible has licensed the underlying technology and formulation to Quoin.
• Does Skinvisible develop obesity treatments?
  Skinvisible has developed Invisicare-based transdermal formulations for obesity and glucose-controlling agents, including GLP-1 receptor agonists, CB-1 receptor antagonists and SGLT-2 inhibitors, and has filed provisional patent applications covering these compositions and methods of delivery.
• How are Skinvisible’s obesity formulations administered?
  The company describes its obesity and glucose-controlling formulations as topical creams or lotions that deliver drugs transdermally without the use of needles, pills or patches, aiming for sustained systemic delivery while avoiding first-pass metabolism.
• What role do strategic partnerships play for Skinvisible?
  Skinvisible emphasizes that it is actively seeking strategic partnerships with pharmaceutical and biotech companies. Partners are expected to take Invisicare-based formulations into clinical development, pursue regulatory approvals and commercialize products, while Skinvisible provides the delivery technology and formulations.
• Is Skinvisible focused only on rare diseases?
  While Skinvisible is involved in rare dermatology indications such as Netherton Syndrome through its license with Quoin, it also targets broader areas such as obesity and other glucose-controlling conditions using its Invisicare transdermal platform.
• On which market does SKVI trade and what is its sector classification?
  Shares of Skinvisible, Inc. trade on the OTCQB market under the ticker SKVI. The company is classified in the pharmaceutical preparation manufacturing industry within the manufacturing sector.